{"name":"Protagonist Therapeutics, Inc.","slug":"protagonist-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":159290000,"netIncome":-130149000,"cash":668188000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Open-label rusfertide","genericName":"Open-label rusfertide","slug":"open-label-rusfertide","indication":"Chronic kidney disease-associated anemia","status":"phase_3"}]}],"pipeline":[{"name":"Open-label rusfertide","genericName":"Open-label rusfertide","slug":"open-label-rusfertide","phase":"phase_3","mechanism":"Rusfertide is a human erythropoietin receptor agonist.","indications":["Chronic kidney disease-associated anemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQLWI0MjVVcWhMX1hPMzBfNV9tR2Q2T3RzSncyMWtVeWxvT0lUOXFFcE1QVFZ5NlYzQUZnUkNndWd2V2oxZHZSR0hBQWhtM04tUTk5ZkFNWEIyX2hsT1ZnLVdQX01pMkpDX1gzZ0JzLUdTYnlqQmxxQkUtby12eDZNU0VNbnBKaDJkQkNRMkN6UFBaRXdTSDNlTkllVHJqVjFKRWx3REpDQ3BwanJqdHNiTQ?oc=5","date":"2026-03-18","type":"pipeline","source":"The Business Journals","summary":"How an East Bay company picked up $50 million with another $580 million potentially on the way - The Business Journals","headline":"How an East Bay company picked up $50 million with another $580 million potentially on the way","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxOY0Y0R0VwczF3NE5FTGZhNDhEWFREVHJvMm1VY0tmbmhXRFdEUlpCWDE1RU83eXVwY3BpSE9acGRRQVIxR2x0R1BobUxfZktiUzhQMk1GSlFrcHdwZ2FYLVdTbXY2dmtTdTBCM3l5Y1RrTG9XR000a21Lc2MxTVRrN1Z0Y01IVGpRajJBVEdKYmFnS2Vfc2RfeWhkZktfdUR5Rzd5NU85TU5oMWkzQ3VWcWcyY3VaeGg5N29pVTA4dzlTZjlaNlVBRk8tQXdWRlBwREFXVjFZcGZhLWRFS0lkV2ZUYlFPV0VBWkFmc0d0UmhUcmdoZUVqNkl6YXVnLXZTNE8yVHppWi00Yk9X?oc=5","date":"2026-01-22","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: Protagonist Therapeutics (PTGX), CG Oncology, Inc. (CGON)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPMEc1VFVVWHJ5M3FGZmt1SlAyQi1ROWFpa0pXWDAyVzI4bzFJejVSTlFtUjF5VUJ4dVgwamE3NGRxa3RxWE5uenM1bzVZY1Frd01oVzEtVndJUENva0o5WWJQVUwwRDVRa0JWcm9nMU5ObWtJSEwtT01UTnhPVHJTY2hFb2c3Sno4cEpsd0hIOWJheG9QaTd1TGJrWnRCYTN2U0R1ZmhiWmI3MXdPOXRlSUtPNWZzUlV2ei1wVnp0bnJPRUc4Z3NMeGtCc3J1ZElwN3U0YXdSa2hVQ3UtYjNyOXlGcGI?oc=5","date":"2026-01-07","type":"pipeline","source":"ACCESS Newswire","summary":"Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - ACCESS Newswire","headline":"Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPdkhublhfejdqS0FNOGFBc2dNcjJDTnM4RGxTbmhlbmk4ZWxNcmlhdVpzdEVXNndSY2dwYXVkM3RpNmNiZ3RIM2ZvdVAyWF92ZjFhN3NHYzg3V2xLd2xBVE43R1Jtd282bklOMDNrNGNTa0l3WjZvb3NZYUtUUTNIYw?oc=5","date":"2025-10-13","type":"deal","source":"Yahoo Finance","summary":"J&J in talks to acquire Protagonist Therapeutics - Yahoo Finance","headline":"J&J in talks to acquire Protagonist Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOUzRDMVBqZnloZlpOVmtUZzFyZU5Xc2RmZjFfNjR5bTBRMEJodnA2a2ZZc09rTTR1WWdHV3h5UFFCNEdWNTBGUmlkS2FZbk9pMEgyN3VwUTNtc2pnclBsb3VDT3lZUzJJeWJldDlyM2ZGdUJwRThIN2ZOSTZKZ3JtZTRIX2tHOGdpTmVQbFRn?oc=5","date":"2025-10-13","type":"deal","source":"Yahoo Finance","summary":"Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal - Yahoo Finance","headline":"Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-11","type":"earnings","source":"simplywall.st","summary":"Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues - simplywall.st","headline":"Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOSThFSl8ycjdwZ2RIU3F3amxIbUJKdVJvRkJ2c21zUlFoc0FNSk9mZGtKV180U1JkXzRqRXY5djBkUEcwZ3FmUXJfVTM2RklYcEZmN0xPTjd0WGZOeXhLNGRhSDB1TVBMMFhSdDdiR2ExSE16ZWt6eDctQUpfTE4waW5hUTRHT05QeFJzNnF1cEktQ191WEVCZ3c0dzhMbkVEb0J0SzBBbERKVkEzZnN3R0czQzRJc2liOFI5NXJXUVoyVmhZU0RzMzMxcEt0VnlOVF9oTA?oc=5","date":"2025-10-10","type":"deal","source":"Reuters","summary":"Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - Reuters","headline":"Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQbFFjdXhqZmVSaktjV2ZVNzBfTDZxTG83MHJfM2lYazJic0JRYk90OW9NdEEtejdkLW5QYUV1N0tYY0ZBOGdvVkF6MWxCRFFHQnhyQ1hBOVp3VVFrdVBtWkJmcnByS0JaQnp2SFpVUVhDbHJyTTFwV1pjZmN1emQ3aWdCUXpFbmlTdmNrQ3VyMzF2TVZNR2k4WFBPWXpicTVG?oc=5","date":"2025-10-10","type":"deal","source":"wsj.com","summary":"Exclusive | Johnson & Johnson in Talks to Buy Protagonist Therapeutics - wsj.com","headline":"Exclusive | Johnson & Johnson in Talks to Buy Protagonist Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPYmhGNEsxNTZIdEFod0RuRDRqbUlXMzNvR25oNWdUdHlDVHc4aUpaUDVoWkNwZUtmTHJhUWZ3UzVfaERIUnNWc0hIemw0V2R0OW5mSlFKV0k4YzNHdXRJaUJQU1U3dDRfOEJOWGpSZUFCZHZQTnhQWDl2T1lvZ2ZrVVJsMXk0cEx2NC1hOHFfZ19JamczNDFOUEVsSkRLMnBGM2x2bjZvMFpuWnFhc2YzdQ?oc=5","date":"2025-10-10","type":"deal","source":"Bloomberg.com","summary":"Johnson & Johnson in Talks to Buy Protagonist Therapeutics: WSJ - Bloomberg.com","headline":"Johnson & Johnson in Talks to Buy Protagonist Therapeutics: WSJ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNZ1NGVEk5d0tXRnBEcVljLVdCT3BfRjhlUUdlMXdMRTVYMFhDMTlyXzVFR3dTUDFmdFNrWlY3aE4yVnJXVm1WcGxNS1F6X2lqaXpIbDk3eFNUSXJfa1psU1VEdE1ZME1mYzZFY1NzSU9sTEV3RVQ4azBUaGdOeWh3OEFDQXFhNXVLeDR1b1RRZHpHRFI5QURnb01aTVhrZw?oc=5","date":"2025-10-10","type":"deal","source":"Fierce Biotech","summary":"J&J in talks to buy immunology partner Protagonist: WSJ - Fierce Biotech","headline":"J&J in talks to buy immunology partner Protagonist: WSJ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPNmFmdGQ3WF9oMERhdEVXOHpsSDk2U3VIVV90WlRvSUJTUjFfWkRpb182cTB6NmtBOF8tUjVSbTBrenJmZ2gzN0ZiOFFJNXRMNjNITEhUWDBrbVNlNXo4MUZCSi1OcjBJaDJKU0ZPclZBeVVsQzN4SFd1bVhoRGVBYzVjb0NGYXZYODRXN0d5NTI5Tk1iQWUzQUZxdlhYYzhxY1N0cWQ0RkMydXJrLWI4M1J1Z2Y2OEJqMWMw?oc=5","date":"2025-10-10","type":"deal","source":"Sahm","summary":"Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report - Sahm","headline":"Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOc1lKYTF1Z3JmakgzandJNjVaUUdxdUNMcldRSWNSc2VYcUViTnJVS3I2a0ROVTBwUUZzUDd4VW16VkVKNzNvUXFTZlRpRlZpaE5DUlJFWW9naDNzV2ZueEcwdV9DZGIwdXI3dzZNTzc4NzhORThCOTA2eEpVOTNfblhvZVc0OW5ieHIxV09sVnJqZw?oc=5","date":"2025-02-22","type":"pipeline","source":"SEC.gov","summary":"PROTAGONIST THERAPEUTICS, INC._December 31, 2024 - SEC.gov","headline":"PROTAGONIST THERAPEUTICS, INC._December 31, 2024","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":159290000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-130149000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":668188000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}